top of page
Microglassification image.webp

Drug Delivery Made Simple

Lindy Biosciences has developed highly concentrated suspensions of biologics that enable subcutaneous delivery. The company’s proprietary Microglassification™ technology produces spherical, dense, stable particles of a therapeutic protein. Microglassification™ uses common organic solvents to rapidly (within seconds) and gently remove water from protein solutions.

Microglass close up.jpg


Microglassification™ gently removes the water from solutions of proteins, or other biologics, resulting in solid, spherical, amorphous microbeads. In this dry state, biologics are stable enough for long-term storage, transport, or incorporation into drug delivery formulations.

Microglassification Technology

High-Concentration Biologics

Many clinically vital biologics, in particular monoclonal antibodies (mAbs), require higher doses than are currently possible via subcutaneous injection. Dissolving antibody in a volume small enough for subcutaneous delivery results in solutions that are too viscous to inject through a needle, or too unstable to maintain a reasonable shelf-life. By combining the stability of solid mAbs and the beneficial properties of injectable suspensions, we can vastly improve the administration of biotherapeutics.


• High protein concentration
• Stable (formulated as a solid)
• Low viscosity

The video shows one of our early experiments: Microglassification™ of a single protein microdroplet, held on the end of a glass capillary micropipette. The resulting solid microbead consists of pure protein at >1 gram/milliliter. Currently-used methods mimic this experiment, producing protein microdroplets on a bulk scale and dehydrating those microdroplets within seconds.

bottom of page